Title:Innovative Nanomaterials for Targeting Hypoxia to Improve
Treatment for Triple-negative Breast Cancer
Volume: 18
Issue: 4
Author(s): Suman Kumar Ray and Sukhes Mukherjee*
Affiliation:
- Department of Biochemistry, All India
Institute of Medical Sciences, Bhopal, Madhya Pradesh, 462020, India
Keywords:
Triple-negative breast cancer, hypoxia nanomaterials, hypoxia-inducible factor 1, tumor microenvironment, clinical outcomes, patent.
Abstract: Triple-negative breast cancer (TNBC) is an aggressive breast cancer with a
high rate of metastases, a short overall survival time, and a poor response to targeted therapy.
Improving tumor hypoxia by lowering the oxygen consumption rate of breast tumor
cells is a powerful strategy. A viable way to address this issue is to improve therapeutic
efficacy by improving the effectiveness of radiation and overcoming drug resistance in
TNBC treatment by controlling hypoxia in the tumor microenvironment. The failure of
radiation and chemotherapy in TNBC is frequently caused by hypoxia. In TNBC therapy,
novel nanomaterials are used for oxygen delivery or generation to affect the tumor microenvironment
to improve the effects of ionizing radiation using nanoplatforms. One of the
growing fields is novel nano-based drug delivery devices for hypoxic regions and hypoxia-
inducible factor-1 (HIF1) targeted therapeutics. Biocompatible nanoparticles may be
used in the treatment of TNBC patients in the clinic. Because of the rising market and
competition, intellectual property rights (IPR), patents, and tactics may be critically considered.
To better comprehend the current state of IPR and patents in cancer nanotechnology,
this overview examines recent advances and sophisticated protection measures in
this area.
